Compare DexCom, Inc. (DXCM) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Funko Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Funko Inc trades at $6.44 (market cap $363.97M). The key difference: DexCom, Inc. is far larger — about 87.5× Funko Inc's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,422,651). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Funko Inc for 33 Days on average.
| DXCM | FNKO | |
|---|---|---|
Market Cap | $31.86B | $363.97M |
Volume | 3,607,070 | 1,422,651 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $7.10 |
52-Week Low | $54.84 | $2.81 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $584.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Funko (FNKO) trades at $6.50, up 3.01% today, with strong technical momentum showing bullish moving average signals. The company reported mixed Q2 2026 results with revenue growth of 7% to $207.7 million and significant EBITDA improvement, though net income remains negative. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 16.6% upside potential from current levels.
Investment outlook balances improving operational metrics against persistent profitability challenges. The stock offers potential upside based on analyst targets and recent earnings beats, but risks include negative net margins, volatile cash flows, and high debt levels that could pressure shareholder returns in a competitive collectibles market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
